case_images: PMC3764956_01
case_images: Chest CT before disease progression (a), when disease progression was first confirmed (b), 1 month after disease progression (c), 2 weeks after discontinuation of crizotinib (d), and 5 weeks after discontinuation of crizotinib (e).
case_images: cro-0006-0430-g01.jpg
case_images: PMC3764956_01_cro-0006-0430-g01.jpg
case_images: F1
case_images: A partial response was achieved and maintained for 10 months (fig. 1a); however, regrowth of the mediastinal lymph nodes was confirmed (fig. 1b). Crizotinib was continued for 1 month, and the size of the lymph nodes increased slightly (fig. 1c). Chest CT before the start of the experimental therapy (2 weeks after discontinuation of crizotinib) showed evident increase of the mediastinal lymph nodes but he did not complain of any symptoms (fig. 1d). However, 1 week after the start of the experimental therapy (3 weeks after discontinuation of crizotinib), he started to complain of dyspnea and dysphagia, and chest CT revealed a marked increase of the mediastinal lymph nodes accompanying marked stenosis of the bronchus and esophagus (5 weeks after discontinuation of crizotinib) (fig. 1e).